复发性滤泡性淋巴瘤治疗新药copanlisib的药理作用与临床评价  

Pharmacological and clinical evaluation of copanlisib in the treatment of relapsed follicular lymphoma

作　　者：李春杏 刘桦[1] 孙桂凤[2] 王洋[2] 刘朋[2] 封宇飞[2] 

机构地区：[1]航天中心医院药剂科,北京100049 [2]北京医院国家老年医学中心药学部药物临床风险与个体化应用评价北京市重点实验室,北京100730

出　　处：《临床药物治疗杂志》2018年第1期27-31,共5页Clinical Medication Journal

摘　　要：滤泡性淋巴瘤发病率居非霍奇金淋巴瘤第2位,因其缓解后易复发,给临床治疗带来极大困难。2017年9月,FDA加速批准磷脂酰肌醇3-激酶抑制剂(PI3K抑制剂)copanlisib上市,用于至少接受过两次全身治疗的成人复发性滤泡性淋巴瘤。临床研究显示,copanlisib有较好的客观缓解率。本文就其药理作用、临床评价、安全性及用法用量等做一综述。The morbidity of follicular lymphoma（FL） is second in non-Hodgkin＇s lymphoma（NHL）. FL is easy to relapse after remission, being very difficult to control. It was preferentially approved as a PI3 K inhibition for the treatment of relapsed FL in adult patients receiving at least two prior therapies by FDA in September 2017. Good objective remission rate was obtained in clinical studies. The pharmacological actions, clinical evaluation, safety, dosage and administration were reviewed in this paper.

关 键 词：copanlisib 滤泡性淋巴瘤 磷脂酰肌醇3-激酶抑制剂 复发性 药理作用 临床评价 安全性 

分 类 号：R979.1[医药卫生—药品]